課程基本資料
系所 / 年級Department/Grade-Level
生物醫學研究所碩士班 1年級
課號 / 班別Course Code
M9M000041 / A
學分數Credits
2 學分
選 / 必修Elective / Required
選修(Elective)
科目中文名稱Course Title (Chinese)
腫瘤標靶治療與抗藥性(一)
科目英文名稱Course Title (English)
Tumor targeted therapy & drug resistance (I)
負責教師Instructor
黃偉謙(Wei-Chien Huang)
開課期間Course Load
一學期
人數上限Enrollment Max.
70 人
已選人數Enrollment Taken
6 人
抽籤自動遞補等候人數Number of the waiting list after ballot
0 人
備註Memo
全英文授課,與生化所合班 全英語授課(Full English course)
可選學制 (availability)
大學部
不可選
二技部
不可選
碩士班
1年級 至4年級
博士班
不可選

修讀他所『碩士班可供博士班下修課程』是否認列為博士班畢業學分,請先向所屬研究所確認,以免日後所修學分不予認列。

請各位同學遵守智慧財產權觀念;請勿非法影印。

教學綱要
課程概述Course Description
以細胞表面標記及各種訊息傳遞途徑之作用分子做為標靶的治療,成為目前腫瘤治療的新趨勢,然而抗藥性的形成仍是臨床上標靶治療藥物發揮療效所面臨的主要問題。
教學目標Course Objectives
經由本課程的選修,期望學生得以瞭解各種癌症標靶治療藥物的作用原理及形成抗藥性的主要機制。 Targeted therapies using specific inhibitors against cell surface markers and signal transduction molecules have been viewed as promising strategies for cancer therapy. However, the development of drug resistance remains the major issue limiting their therapeutic efficacy. This lecture will (1) introduce major cellular signaling pathways involved in cancer development to identify potential targets for therapeutic interventions, (2) describe how targeted therapies may work in the treatment of various tumors, and (3) assess the current knowledge of the molecular mechanisms conferring to intrinsic/acquired resistance of targeted therapies.
先修科目Prerequisites
教學方式Teaching Methods
講課 Lecturing 學生上台報告、角色演練 Oral presentation, Role playing
評量方式Assessment
個人上台報告 Oral Report 出席狀況 Class attendance
期中考試或報告成績40% 期末考試或報告成績40% 平時上課討論及發問情形20%
參考書目Reference
1.Targeted Cancer Therapy/edited by Razelle Kurzrock, Maurie Markman/Humana Press, Totowa, NJ/2008 2.Targeted Therapies in Cancer Myth or Reality? /Colotta, Francesco and Mantovani, Alberto./SpringerLink/ 2008 3.Targeted Therapies in Oncology-Guiseppe Giacone and Jean-Charles Soria 4.Biomedical Journals
教學進度Course Schedule
2022/09/14 抗癌藥的發展 Anticancer Drug Discovery and Development 黃偉謙(Wei-Chien Huang)
2022/09/21 腫瘤標靶治療藥物概要 Overview of targeted therapies in cancer 黃偉謙(Wei-Chien Huang)
2022/09/28 訊息傳遞分子抑制劑 Signal transduction inhibitors 黃偉謙(Wei-Chien Huang)
2022/10/05 胜?標靶藥物 I Peptides as drugs I 余永倫(Yung-Luen Yu)
2022/10/12 胜?標靶藥物 II Peptides as drugs II 余永倫(Yung-Luen Yu)
2022/10/19 免疫調控藥物 Immune modulator 許榮茂(Hsu,Jung-Mao)
2022/10/26 PI3K/Akt/mTOR pathway 抑制劑 Inhibiting the PI3K/Akt/mTOR pathway 黃偉謙(Wei-Chien Huang)
2022/11/02 Farnesyl transferase 抑制劑 Farnesyl transferase inhibitors in Cancer 黃偉謙(Wei-Chien Huang)
2022/11/09 期中考 Mid exam 黃偉謙(Wei-Chien Huang)
2022/11/16 HER2 標靶治療藥物 HER2 inhibition and clinical Achievements 黃偉謙(Wei-Chien Huang)
2022/11/23 泛表皮生長因子受體抑制劑 Pan-HER inhibitors 黃偉謙(Wei-Chien Huang)
2022/11/30 inhibitorsEGFR/HER2 抑制劑之抗藥性 Drug resistance to EGFR/HER2 inhibitors 黃偉謙(Wei-Chien Huang)
2022/12/07 內皮細胞增殖作用藥物 Endothelial Cell Propagation Targeting 黃偉謙(Wei-Chien Huang)
2022/12/14 胰島素生長因子受體抑制劑 TRAIL modulators 黃偉謙(Wei-Chien Huang)
2022/12/21 PDGFR 與 c-KIT抑制劑 Signal transduction inhibitors: PDGFR and c-KIT inhibitors 黃偉謙(Wei-Chien Huang)
2022/12/28 PKC 抑制劑 PKC inhibitors in treatment of NSCLC 鄒瑞煌(Ruey-Hwang Chou)
2023/01/04 Aurora kinase 抑制劑 Aurora kinase inhibitors 鄒瑞煌(Ruey-Hwang Chou)
2023/01/11 期末考 Final exam 黃偉謙(Wei-Chien Huang)